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ABSTRACT 
 
Background: Cholesteryl ester transfer protein (CETP) plays a main role in high-density lipoprotein 
metabolism. CETP gene possesses several single nucleotide polymorphisms which have been associated with 
plasma high-density lipoprotein cholesterol (HDL-C) concentrations. The aim of this study was to determine 
the association of CETP -629C/A and I405V polymorphisms with coronary artery disease (CAD) in Iranian 
population.  Methods: The presence of two CETP gene polymorphisms -629C/A and I405V were studied in 
187 unrelated CAD cases and 136 controls. All the samples were clinically examined and lipid profile was 
estimated. Genotyping was performed using polymerase chain reaction/restriction fragment length 
polymorphism method.  Results: The frequency of -629C/A and I405V allelic variants were found to be 0.732 
and 0.366 in cases and 0.658 and 0.348 in controls, respectively. The frequency of A allele of -629C/A 
polymorphism in cases was significantly higher than that of controls. HDL-C in AA genotype was higher than 
CA and CC genotypes in controls. No significant effect of II, IV and VV genotypes was found in lipid 
profiles. Conclusion: No significant association was found between CETP I405V polymorphism and 
increased risk of CAD in Azeri population studied. AA genotype of -629C/A increased HDL but the risk of 
CAD in this genotype might be higher than CC genotype.  Iran. Biomed. J.  13 (2): 103-108, 2009 
 
Keywords: Cholesteryl ester transfer protein (CETP) gene, I405V, High-density lipoprotein (HDL) cholesterol,-629C/A 
 
 
INTRODUCTION 
 
oronary artery disease (CAD) has a multi-
factorial etiology with many established risk 
factors [1]. Disturbances in lipoprotein 
metabolism play a major role in atherogenesis. A 
strong inverse relation exists between high-density 
lipoprotein cholesterol (HDL-C) plasma level and 
the risk of CAD [2]. Low HDL-C rather than 
elevated LDL-C is the most frequent lipid 
abnormality in men who present with coronary heart 
disease [3]. Cholesteryl ester transfer protein 
(CETP) plays a central role in HDL-C metabolism 
by shuttling cholesteryl esters from HDL particles to 
apolipoprotein B-containing particles in exchange 
for triglycerides [4]. The role of CETP in general 
population and how it may modulate the risk for 
CAD is unclear [5, 6]. CETP gene has been 
localized on chromosome16q21 and consisted of 16 
exons [Accession id: ENSG00000087237]. The gene 
possesses several different single nucleotide 
polymorphisms (SNP) [7]. Some of these affect the 
CETP activity and HDL-C concentrations and have 
been studied as predictors of cardiovascular diseases 
[8].  
The -629C/A (rs1800775) polymorphism is a 
functional SNP present in 629-bp upstream of the 
transcription start site in the promoter region of the 
CETP gene. This promoter polymorphism modulates 
CETP gene transcriptional activity in vitro [9]. 
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Importantly, it has been documented that this variant 
is involved in regulating plasma CETP levels [10]. 
The A-629 allele has been associated with lower 
CETP mass and higher HDL-C than the C allele 
[11]. 
     The I405V (rs5882) polymorphism, a very 
common SNP, located in exon 14 of the CETP gene 
is caused by A to G transition in position 20206. It is 
characterized by alteration in the primary structure 
of the protein having either an isoleucine or a valine 
at codon 405 [12]. VV genotype of this 
polymorphism has been associated with lower 
plasma CETP concentration and higher HDL-C 
concentration [13].  
    The aim of the present study was to determine the 
prevalence of -629C/A and I405V polymorphisms in 
control and CAD patients and to examine if the 
subjects lipid profiles is influenced by the above 
mentioned CETP polymorphisms. 
 
 
MATERIALS AND METHODS 
 
Subjects. Subjects were originated from Azeri 
ethnicity that attended for coronary angiography at 
the Emam Reza and Shahid Madani Hospitals in 
Tabriz (Iran). The subjects, who matched by age and 
sex, with abnormal (stenosis in coronary arteries) 
and normal coronary angiogram, were recruited as 
cases and controls, respectively. In total, 187 
unrelated CAD cases and 136 controls were studied. 
The personal and clinical data were collected by a 
questionnaire. The study protocol was approved by 
the Tabriz University of Medical Sciences Ethics 
Committee and informed consent was obtained from 
all patients. Those with acute coronary bypass 
surgery, angioplasty, acute coronary syndromes, 
diabetes, hepatic or renal, uncontrolled 
hypothyroidism, neoplasia and receiving lipid-
lowering drugs were excluded from the study. 
      
Blood sampling and biochemical determinations. 
Venous blood sample for, glucose, creatinine, lipids, 
lipoproteins and DNA analysis was collected from 
the subjects after an overnight fasting. Glucose, total 
cholesterol and triglyceride were assessed by 
standard enzymatic procedures. HDL-C and LDL-C 
were measured using direct method and 
apolipoprotein A1 and apolipoprotein B levels were 
determined by immunoturbidimeteric method. 
Creatinine was measured by Jaffe method to exclude 
renal patients. All biochemical tests were performed 
in serum using by BT 3000 automatic analyzer and 
commercial kits ( Pars Azmon Co., Iran). CETP 
concentration was measured in serum using the 
CETP test ELISA kits produced by ALPCO 
Diagnostic (USA). 
 
Molecular analyses. DNA was extracted using 
standard phenol-chloroform procedure. CETP I405V 
and -629C/A polymorphisms were determined by 
polymerase chain reaction/restriction fragment 
length polymorphism as described previously [14]. 
Shortly, the 308-bp PCR products of CETP I405V 
and 127-bp PCR products of CETP -629C/A were 
digested using RsaI and AvaI, respectively. The 
result and PCR fragments were visualized by silver 
staining method (Fig. 1). 
 
Statistical analysis. Continuous variables were 
reported as the mean ± SD. All statistical analyses 
were performed using statistical package SPSS 11.5 
for windows and a P<0.05 was considered 
statistically significant. Allele frequencies were 
calculated from the genotype counts. The observed 
genotype counts were compared with those expected 
under Hardy-Wienberg equilibrium with a χ2 test. 
The genotypes were compared with lipid profile 
values using one-way ANOVA followed by Tukey's 
multiple comparison tests. 
 
(a) 
 
 
 
(b) 
 
 
 
 Fig. 1. Polyacrylamide gel electrophoresis for CETP 
polymorphisms. (a) I405V polymorphism.  Lane 1 is DNA 
marker, lane 2, 3, 5, 8, 10 and 12 are related to the II genotype, 
lane 4, 7 and 11 are related to the IV genotype, lane 6 and 9 are 
related to the VV genotype. Lane 13 is negative control  
(blank), Lane 14 is DNA control (uncut). (b) -629C/A 
polymorphism.  Lane 1 is DNA marker, lane2 -5 and 8 and 
11and 13 are related to the AA genotype, lane7, 10 and 12 are 
related to the CA genotype, lane 6 and 9 are related to the CC 
genotype. Lane 14 is negative control (blank), Lane 15 is DNA 
control (uncut). 
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                                        Table 1. Baseline characteristics of study subjects. 
 
Characteristic control CAD patients P value 
Age (years) 52.80 ± 11.1 54.60 ± 9.70 0.085 
BMI   (kg/m2) 26.90 ± 4.0 27.10 ± 4.14 0.640 
Cholesterol (mg/dl) 172.60 ± 42.0 176.60 ± 46.70 0.226 
Triglyceride (mg/dl) 184.90 ± 118.4 190.90 ± 101.80 0.990 
HDL (mg/dl) 38.90 ± 11.4 36.70 ± 9.90 0.361 
LDL (mg/dl) 96.70 ± 35.5 101.60 ± 41.20 0.219 
Apo AI (mg/dl) 125.90 ± 21.4 120.50 ± 19.50 0.051 
Apo B (mg/dl) 102.70 ± 26.3 104.30 ± 30.00 0.253 
CETP (µg/ml) 2.31 ± 0.92 1.98 ± 0.75 0.011 
   
                                      Values are mean ± S.D., P<0.05 is significant. 
 
 
RESULTS 
 
The characteristics and the lipid profile of the case 
(CAD) as well as control groups are summarized in 
Table 1. The mean age of cases and controls was 
54.6 ± 9.7 and 52.8 ± 11.1, respectively. There was 
no significant difference between CAD and control 
groups regarding the mean concentrations of plasma 
lipids, body mass index and age. The genotype 
frequencies of the 2 polymorphisms of CETP gene 
in CAD patients and controls are shown in Table 2. 
The frequencies of A allele of -629C/A and V allele 
of I405V were 0.732 and 0.366 in cases and 0.658 
and 0.348 in controls, respectively. The frequency of 
A allele of -629C/A polymorphism in cases was 
significantly higher than that of control group. 
The allele frequencies of CETP gene 
polymorphisms in the present study are compared 
with some major populations (Table 3). This study 
represents a higher frequency of -629A allele 
compared to that of Asian, Caucasians, African 
Americans and Tamilians. No significant effect of 
different I405V alleles was found on lipid profiles.   
When CETP level was analyzed among the three 
-629C/A polymorphisms, mean value was lower in 
the AA group compared to the CA and CC groups 
(P<0.04 and P<0.01, respectively). HDL-C in AA 
genotype was higher than CA and CC genotypes in 
controls (Table 4).   
 
 
DISCUSSION 
 
 CETP has both pro- and anti-atherogenic effects 
[15, 16].Various mutations in the CETP gene seem 
to cause changes in the HDL cholesterol level. VV 
genotype of I405V polymorphism is reported with 
low CETP, high cholesterol and elevation of the risk 
for CHD [17]. In this study, the relationship of 
I405V polymorphism in CETP gene with plasma 
CETP level, lipids, lipoproteins and coronary 
atherosclerosis was investigated. We failed to show 
a significant role of I405V variation of CETP either 
on lipoprotein metabolism or on atherogenesity in 
this study. The frequency of 405V allele was 0.35 in 
control group which is almost matches that of seen 
in Caucasians (0.318) and lower than that in Asians 
[14, 18]. It was shown in several studies that carriers 
of 405V allele have increased HDL-C concentration 
[11, 19],  but  in  the  present   study,  there   was  no     
 
                  Table 2. Genotype frequencies of the two polymorphisms of CETP gene. 
 
CETP genotype 
  %Frequency (number) 
 
Control 
 CAD patients 
I405V   1 VD 2 VD 3 VD Total 
II 43.000 (58) 45.300 (29) 39.300 (24) 40.300 (25) 41.700 (78) 
IV 44.400 (61) 45.300 (29) 45.900 (28) 38.700 (24) 43.300 (81) 
VV 12.600 (17) 9.400 (6) 14.800 (9) 21.000 (13) 15.000 (28) 
Total 100.000 (136) 100.000 (64) 100.000 (61) 100.000 (62) 100.000 (187) 
V allele 0.348 0.320 0.377 0.403 0.366 
-629C→A      
AA 44.900 (61) 56.300 (36) 60.700 (37) 59.700 (37) 58.800 (110) 
CA 41.900 (57) 32.800 (21) 27.900 (17) 25.800 (16) 28.900 (54) 
CC 13.200 (18) 10.900 (7) 11.400 (7) 14.500 (9) 12.300 (23) 
Total 100.000 (136) 100.000 (64) 100.000 (61) 100.000 (62) 100.000(187) 
A allele 0.658 0.771 0.746 0.726 0.732 
 
The coronary angiography exhibited stenosis greater than %50 of one vessel was graded as 1VD, 2 vessels stenosis 
greater than %50 was graded as 2VD and 3 vessels stenosis greater than %50 was graded as 3VD. 
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         Table 3. Comparison of allele frequencies of subjects with other major populations. 
 
Other populations  Present study 
Alleles Tamilians [18] 
(n = 171) 
Caucasians [17] 
(n = 2188) 
African Americans [17] 
(n = 30) 
Asians [17] 
(n = 148) 
 Non-CAD 
(n = 136) 
CAD 
(n = 187) 
V * 0.530 0.318 0.611 0.617  0.348 0.366 
A ** 0.640 0.482 0.573 0.500  0.658 0.732 
        P<0.05 is significant. V*, V allele of I405V (P = 0.35 for non CAD and CAD); A**, A allele of -629C/A (P = 0.02). 
 
 
change in HDL-C among the I405V genotypes. V 
allele frequency was 0.320, 0.377 and 0.403 in 1VD, 
2VD and 3VD, respectively but they were not 
statistically significant. 
 Another genetic variant in CETP gene is -629C/A 
promoter polymorphism [20]. It is likely that the -
629C/A CETP gene variant directly affects 
regulation of plasma CETP mass levels [21]. The 
frequency of A allele of CETP-629C/A 
polymorphism in this study was 0.66 in control 
group and it corroborates with the fact that Asian 
have a higher frequency of the -629A allele 
compared to that of found in the European 
populations [22]. In this study, there was an increase 
in HDL-C in carriers of AA genotype compared to 
CC in control but there was no significance 
difference in CAD patients. A allele has higher 
prevalence in CAD patients but it is not protective 
for CAD. Remarkably, CETP gene variations that 
result HDL-C increase may not affect cardiovascular 
protection [23]. In fact, in the largest prospective 
population based study to date, recently was 
documented that the -629A allele, which determine a 
lower plasma CETP mass and a higher HDL-C are 
associated with increased cardiovascular risk, 
particularly when the effect of these CETP gene 
variants on HDL cholesterol is taken into account 
[24]. 
     It is therefore of relevance to explore potential 
mechanisms responsible for this paradoxical 
relationship. Among other possibilities, an influence 
on CETP-mediated processes affecting the ability of 
plasma to stimulate cellular cholesterol removal 
could be involved in the apparent cardio protective 
role of CETP gene variation that relates to higher 
expression of this lipid transfer protein [25]. The -
629C/A CETP promoter variant does not alter the 
molecular structure of this lipid transfer protein but 
affects its circulating mass and, hence, the amount of 
active CETP in serum [26].    
 One of the limitations in the study is the use of 
coronary stenosis for the magnitude of coronary 
atherosclerosis. The region that appears normal in 
coronary angiography would often be considered 
atheromatous when examined by intravascular 
ultrasound. Thus the extent of the stenosis does not 
always indicate the clinical severity of CAD [27].    
 
 
  Table 4. distribution of anthropometric and metabolic parameter in different CETP genotype groups. 
 
CETP I405V 
Non-CAD  CAD patients 
II IV VV  II IV VV 
Age (year) 52.50 ± 12.10 53.30 ± 11.10 53.00 ± 9.90 55.80 ± 9.90 56.20 ± 9.60 54.90 ± 9.80 
BMI 26.70 ± 4.30 26.80 ± 3.50 28.30 ± 4.40 26.90 ± 4.00 27.50 ± 4.50 26.50 ± 3.40 
TC (mg/dl) 170.00 ± 41.40 175.00 ± 39.50 172.00 ± 49.30 174.00 ± 50.50 177.00 ± 44.70 184.00 ± 41.10 
TG (mg/dl) 176.00 ± 107.10 179.00 ± 77.60 186.00 ± 66.20 194.00 ± 88.90 187.00 ± 100.90 193.00 ± 137.20 
HDL-c (mg/dl) 38.20 ± 10.80 39.00 ± 12.90 40.60 ± 8.30 36.30 ± 8.90 37.10 ± 9.70 37.40 ± 12.60 
LDL-c (mg/dl) 93.80 ± 32.90 100.30 ± 33.10 95.00 ± 44.80 99.20 ± 46.40 102.30 ± 35.80 107.80 ± 41.30 
apo AI (mg/dl) 126.70 ± 19.70 123.90 ± 23.80 129.70 ± 20.00 121.70 ± 17.80 118.90 ± 20.40 122.80 ± 21.60 
apo B (mg/dl) 103.10 ± 25.70 103.10 ± 27.40 102.40 ± 25.70 103.40 ± 35.00 106.10 ± 27.60 102.90 ± 21.30 
CETP (µg/ml) 2.40 ± 0.89 2.16 ± 0.98 2.29 ± 1.04 2.14 ± 0.77 1.93 ± 0.74 1.70 ± 0.57 
       
CETP -629C/A AA CA CC AA CA CC 
Age (year) 52.40 ± 12.60 52.20 ± 10.30 53.70 ± 10.70 55.80 ± 9.90 55.80 ± 9.50 56.00 ± 9.60 
BMI 26.40 ± 4.10 27.20 ± 3.70 27.80 ± 4.40 27.10 ± 4.50 27.00 ± 3.70 26.80 ± 3.50 
TC (mg/dl) 170.00 ± 35.70 170.00 ± 50.10 176.00 ± 29.30 178.00 ± 49.00 173.00 ± 42.30 180.00 ± 46.50 
TG (mg/dl) 164.00 ± 68.40 182.00 ± 90.40 223.00 ± 133.70 188.00±111.30 194.00 ± 96.50 195.00 ± 61.10 
HDL-c (mg/dl) 41.90 ± 12.40* 36.60 ± 10.40* 35.10 ± 8.70* 38.10 ± 9.90 34.80 ± 8.60 34.90 ± 11.00 
LDL-c (mg/dl) 95.70 ± 30.60 97.20 ± 40.10 96.50 ± 27.00 101.80 ± 43.90 99.50 ± 36.30 105.80 ± 39.90 
apo AI (mg/dl) 129.90 ± 24.80 121.10 ± 18.20 126.40 ± 16.70 122.70 ± 19.30 114.80 ± 17.40 123.80 ± 23.50 
apo B (mg/dl) 99.80 ± 24.10 103.90 ± 29.20 110.50 ± 22.40 103.40 ± 28.20 106.60 ± 34.80 103.70 ± 26.90 
CETP (µg/ml) 2.19 ± 0.99 2.33 ± 0.90 2.51 ± 0.99 1.82 ± 0.66 1.99 ± 0.69 2.74 ± 0.82 
 
Values are mean ± S.D., *The mean difference is significant by Tukey's test at the 0.05 level. 
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In conclusion, in the present study CETP mass 
level decreased and HDL-C increased by -629 C→A 
polymorphism but this high HDL-C didn't reduced 
risk of CAD. We failed to show a significant role of 
I405V genotypes either on lipoprotein metabolism 
or on atherogenesity. 
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